Product Information
MESALAMINE 4 GM/60 ML ENEMA is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.1759 per ML under NDC 45802009828. Its NADAC has been published 441 times since Nov 28, 2013.
FDA first approved this application on Sep 17, 2004. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Mesalamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
4 g/60mL
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802009828
Classification
Generic
Dosage Form
ENEMA
Route
RECTAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
Generic (ANDA)
FDA Application
ANDA076751FDA Approved
9/17/2004
TE Code
AB
On Market Since
10/11/2007
Pharmacological Classes
Price Statistics
The NADAC for MESALAMINE 4 GM/60 ML ENEMA has been published 441 times since Nov 28, 2013, and over the history we have for it it has declined 17.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1759 per ML |
|---|---|
| All-time high | $0.2411 (Sep 14, 2016) |
| All-time low | $0.1662 (Jan 21, 2026) |
| 52-week high | $0.1839 |
| 52-week low | $0.1662 |
| Median price | $0.1868 |
| Average price | $0.1895 |
| Largest weekly change | +29.2% (Aug 17, 2016) |
| Weeks tracked | 441 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 44% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MESALAMINE 4 GM/60 ML ENEMA?
The current National Average Drug Acquisition Cost (NADAC) for MESALAMINE 4 GM/60 ML ENEMA, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.1759 per ML (NDC 45802009828), effective Sep 30, 2026.
How has the price of MESALAMINE 4 GM/60 ML ENEMA changed over time?
Over the history we have for it, the NADAC for MESALAMINE 4 GM/60 ML ENEMA has declined 17.9%. It has been tracked across 441 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MESALAMINE 4 GM/60 ML ENEMA?
Since Nov 28, 2013, the NADAC for MESALAMINE 4 GM/60 ML ENEMA has ranged from a low of $0.1662 (Jan 21, 2026) to a high of $0.2411 (Sep 14, 2016), with a median of $0.1868 per ML.
Are there cheaper alternatives to MESALAMINE 4 GM/60 ML ENEMA?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MESALAMINE 4 GM/60 ML ENEMA, is $0.0984 per ML — about 44% below MESALAMINE 4 GM/60 ML ENEMA.
Who manufactures MESALAMINE 4 GM/60 ML ENEMA?
MESALAMINE 4 GM/60 ML ENEMA (NDC 45802009828) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.